Danny Sugimoto, MD
Internal Medicine · Chicago, ILNPI 1679661821
Payments from drug & device makers
Across 3,004 payments — averaging $1326.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1.1M
- Boehringer Ingelheim$495K
- Novavax Inc$285K
- Amgen$281K
- AstraZeneca$263K
- Pfizer$258K
- plus $1.3M from 18 others
Across 33 payments — averaging $5850.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceutical Holding Company Ltd.$86K
- Pfizer$68K
- Teva Pharmaceuticals USA, Inc.$34K
- Eli Lilly$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 2,469 | $1,131,997 |
| Boehringer Ingelheim | 55 | $495,437 |
| Novavax Inc | 13 | $285,255 |
| Amgen | 6 | $280,560 |
| AstraZeneca | 18 | $262,533 |
| Pfizer | 71 | $258,026 |
| Novartis | 21 | $237,059 |
| Modernatx, Inc. | 24 | $214,662 |
| Eli Lilly | 7 | $178,304 |
| H. Lundbeck A S | 16 | $120,817 |
| Ipsen Innovation | 74 | $86,976 |
| Sanofi-aventis U.S. LLC | 6 | $79,600 |
| Biohaven Pharmaceuticals, Inc. | 11 | $69,420 |
| Sanofi US Services Inc. | 14 | $64,880 |
| Boehringer Ingelheim International GmbH | 140 | $64,300 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $60,995 |
| Teva Pharmaceuticals USA, Inc. | 17 | $45,863 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $28,706 |
| Astrazeneca UK Limited | 10 | $16,180 |
| Kowa Research Institute, Inc. | 2 | $2,300 |
| Novo Nordisk | 6 | $194 |
| Lilly USA, LLC | 9 | $141 |
| Lundbeck LLC | 4 | $80 |
| AbbVie | 1 | $13 |
How this compares
$3,984,297 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
- Naser YamaniChicago$700K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.